ONKOLOGIE www.onkologiecs.cz 80 MONOKLONÁLNÍ GAMAPATIE PŘEHLED PŘÍNOSU DARATUMUMABU PRO LÉČBU VŠECH MONOKLONÁLNÍCH GAMAPATIÍ, ALE I DALŠÍCH NEMOCÍ A VLASTNÍ ZKUŠENOSTI S LÉČBOU 74 PACIENTŮ DARATUMUMABEM, LENALIDOMIDEM A DEXAMETAZONEM 2021;28(4):259-266. doi: 10.1080/13506129.2021.1971192. 134. Milani P, Basset M, Curci P, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Adv. 2020;4(7):13211324. doi: 10.1182/bloodadvances.2020001553. 135. Molina-Andújar A, Tovar N, Cuadrado E, et al. Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. Am J Kidney Dis. 2021;78(5):755759. doi: 10.1053/j.ajkd.2021.02.337. 136. Tsushima T, Suzuki T, Terao T, et al. Light chain deposition disease involving kidney and liver in a patient with IgD myeloma. BMC Nephrol. 2021;22(1):40. doi: 10.1186/s12882021-02246-9. 137. Wiklik-Dziadek M, Jaworek-Troć J, Jurczyszyn A. Amyloidosis, extramedullary plasmacytoma, and light chain deposition disease: impressive results of daratumumab therapy. Pol Arch Interní Med. 2021;131(3):297-298. doi:10.20452/ pamw.15806. 138. Almaani S, Parikh SV, Satoskar AA, et al. Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits. Kidney Int Rep. 2021;6(8):2203-2206. doi: 10.1016/j.ekir.2021.05.008. 139. Coltoff A, Bomback A, Shirazian S, et al. Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy. Clin Lymphoma Myeloma Leuk. 21(8):e674-e677. doi: 10.1016/j.clml.2021.04.011. 140. Torrealba J, Gattineni J, Hendricks AR. Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Lambda Deposits: Report of the First Pediatric Case. Case Rep Nephrol Dial. 2018;8(1):70-75. doi: 10.1159/000488641. 141. Zand L, Rajkumar SV, Leung N, et al. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. J Am Soc Nephrol. 2021;32(5):1163-1173. doi: 10.1681/ASN.2020101541. 142. Contejean A, Larousserie F, Bouscary D, et al. A colonic mass revealing a disseminated crystal storing histiocytosis secondary to indolent multiple myeloma: a case report with literature review. BMC Gastroenterol. 2020;20(1):239. doi: 10.1186/s12876-020-01364-2. 143. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45-59. doi: 10.1038/s41581-018-0077-4. 144. Kastritis E, Theodorakakou F, Roussou M, et al. Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. Br J Haematol. 2021;193(1):113118. doi: 10.1111/bjh.17052. 145. Koike H, Katsuno M. Paraproteinemia and neuropathy. Neurol Sci. 2021;42(11):4489-4501. doi: 10.1007/s10072021-05583-7. 146. Tiew HW, Sampath VS, Gallardo CA, et al. Single-agent daratumumab for refractory POEMS syndrome. Am J Hematol. 2022;97(6):E189-E191. doi: 10.1002/ajh.26517. 147. Leung B, Nelson T, Willenberg R, et al. Failure of Daratumumab Therapy for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes Syndrome. J Clin Neuromuscul Dis. 2021;23(1):56-58. doi: 10.1097/ CND.0000000000000370. 148. Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. Hemasphere. 2020;4(3):e381. doi: 10.1097/ HS9.0000000000000381. 149. Khan M, Stone K, van Rhee F. Daratumumab for POEMS Syndrome. Mayo Clin Proc. 2018;93(4):542-544. doi: 10.1016/j. mayocp.2018.02.001. 150. Sevindik OG, Mutlu YG, Aydin BB, Serin I. First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS). Hemasphere. 2022;6(7):e728. doi: 10.1097/HS9.0000000000000728. 151. Mathew Thomas V, Gilreath JA, et al. Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. Haemophilia. 2021;27(4):e563-e566. doi: 10.1111/hae.14323. 152. Nicol C, Raj L, Guillerm G, et al. Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report. Clin Case Rep. 2020;8(5):900-904. doi: 10.1002/ccr3.2770. 153. Jeryczynski G, Agis H, Eichinger-Hasenauer S, et al. Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy: Breaking a dangerous bond. Wien Klin Wochenschr. 2022;134(11-12):478-482. doi: 10.1007/s00508-022-02012-3. 154. Pinchover LB, Alsharif R, Bernal T. Acquired haemophilia a secondary to multiple myeloma: management of a patient with a mechanical mitral valve. BMJ Case Rep. 2020;13(9):e230798. doi: 10.1136/bcr-2019-230798. 155. Krečak I, Ruščić I, Zlatović JJ, et al. Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone. Ann Hematol. 2021;100(6):1623-1624. doi: 10.1007/ s00277-020-04369-9. 156. Jian Xu, Wenqi Liu, Fengjuan Fan, et al. TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis Front Endocrinol (Lausanne) 2022;13:886961. doi: 10.3389/ fendo.2022.886961 157. Zhang X, Fang M. TEMPI Syndrome: Erythrocytosis in Plasma Cell Dyscrasia. Clin Lymphoma Myeloma Leuk. 2018;18(11):724-730. doi: 10.1016/j.clml.2018.07.284. 158. Sykes DB, Schroyens W. Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab. N Engl J Med. 2018;378(23):2240-2242. doi: 10.1056/NEJMc1804415. 159. Lor M, Cheng M, Liang B, et al. Cheng CE. TEMPI Syndrome With Progressive Telangiectasias Associated With Pulmonary Deterioration. JAMA Dermatol. 2020;156(12):13791380. doi: 10.1001/jamadermatol.2020.2668. 160. Frerichs KA, Verkleij CPM, Bosman PWC, et al. CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. J Transl Autoimmun. 2019;2:100022. doi:10.1016/j.jtauto.2019.100022. 161. Rieger MJ, Stolz SM, Ludwig S, et al. Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. Br J Haematol. 2021;194(5):931-934. doi: 10.1111/bjh.17655. 162. Ofran Y. Daratumumab: new indications revolving around “off-targets”. Haematologica. 2021;106(12):3032-3033. doi: 10.3324/haematol.2021.279487. 163. Jain A, Gupta DK. Daratumumab for refractory warm autoimmune hemolytic anemia. Ann Hematol. 2021;100(5):13511353. doi: 10.1007/s00277-020-04063-w. 164. Khandelwal P, Teusink-Cross A, et al. Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. Br J Haematol. 2021;194(5):e84e89. doi: 10.1111/bjh.17565. 165. Cooling L, Hugan S. Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient. Transfusion. 2019;59(12):3801-3802. doi: 10.1111/trf.15539. 166. Migdady Y, Ediriwickrema A, Jackson RP, et al. Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. Blood Adv. 2020;4(5):815-818. doi: 10.1182/bloodadvances.2019001215. 167. van den Berg J, Kremer Hovinga JA, Pfleger C, et al. Daratumumab for immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6(3):993-997. doi: 0.1182/bloodadvances.2021005124. 168. Gangat N, Bleeker J, Lynch D, et al. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia.Haematologica. 2022 Jun 9. doi: 10.3324/haematol.2022.281398. 169. Zaninoni A, Giannotta JA, Gallì A, et al. The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front Immunol. 2021;12:649441. doi: 10.3389/fimmu.2021.649441. 170. Tomkins O, Berentsen S, Arulogun S, et al. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol. 2020; Jul 11. doi: 10.1002/ ajh.25932. 171. Asawapanumas T, Chanswangphuwana C, Watanaboonyongcharoen P, et al. Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation. Leuk Res Rep. 2022;17:100314. doi: 10.1016/j.lrr.2022.100314. 172. Bathini S, Holtzman NG, Koka R, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 2019;94(8):E216-E219. doi: 10.1002/ajh.25515. 173. Gangat N, Bleeker J, Lynch D, et al. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. Haematologica. 2022. doi: 10.3324/haematol.2022.281398. 174. Henig I, Yehudai-Ofir D, Zohar Y, et al. Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment. Acta Haematol. 2021;144(6):683-687. doi: 10.1159/000515257. 175. Jeyaraman P, Borah P, Rajput P, et al. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells Mol Dis. 2021;88:102464. doi: 10.1016/j.bcmd.2020.102464. 176. Martino R, García-Cadenas I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. Bone Marrow Transplant. 2022;57(2):282-285. doi: 10.1038/s41409-021-01507. 177. Rautenberg C, Kaivers J, Germing U, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020;55(6):11911193. doi: 10.1038/s41409-019-0664-4. 178. Salas MQ, Alahmari A, Lipton JH. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol. 2020;104(2):145-147. doi: 10.1111/ejh.13343. 179. Schuetz C, Hoenig M, Moshous D, et al.Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2(19): 2550-2553. doi: 10.1182/bloodadvances.2018020883. 180. Cole S, Walsh A, Yin X, et al. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):85. doi: 10.1186/ s13075-018-1578-z. 181. Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with Daratumumab inRefractory Systemic Lupus Erythematosus. N Engl J Med. 2020;383(12):1149-1155. doi: 10.1056/ NEJMoa2023325. PMID: 32937047. 182. Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021;17:39-54. doi:10.2147/TCRM.S252592. 183. Humbel M, Bellanger F, Fluder N, et al. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE. Front Immunol. 2021;12:645478. doi: 10.3389/ fimmu.2021.645478. 184. Scheibe F, Ostendorf L, Prüss H, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol. 2022;29(6):1847-1854. doi: 10.1111/ene.15266. 185. Scheibe F, Ostendorf L, Reincke SM, et al. Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. J Neurol. 2020;267(2):317-323. doi: 10.1007/s00415-019-09585-6. 186. Smets I, Titulaer MJ. Antibody Therapies in Autoimmune Encephalitis. Neurotherapeutics. 2022:1-9. doi: 10.1007/ s13311-021-01178-4. 187. Ratuszny D, Skripuletz T, Wegner F, et al. Daratumumab in a Patient With Severe RefractoryAnti-NMDA Receptor Encephalitis. Front Neurol. 2020;11:602102. doi: 10.3389/fneur.2020.602102. 188. Dossier C, Prim B, Moreau C, et al. A global antiB cell
RkJQdWJsaXNoZXIy NDA4Mjc=